3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Multiple Myeloma
87
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Recurrence
16
Burkitt Lymphoma
13
Neoplasms
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Leukemia, Biphenotypic, Acute
7
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
6
Lung Neoplasms
6
Immunoglobulin Light-chain Amyloidosis
6
Neoplasms, Plasma Cell
5
Hodgkin Disease
5
Smoldering Multiple Myeloma
4
Leukemia
4
Carcinoma, Non-Small-Cell Lung
4
Waldenstrom Macroglobulinemia
3
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Neoplasm Metastasis
3
Nausea
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Brain Neoplasms
3
Renal Insufficiency
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell
2
Lymphoma, B-Cell
2
Leukemia, Plasma Cell
2
Interventions
pembrolizumab
19
Paclitaxel
13
Carboplatin
10
Pemetrexed
4
Cisplatin
4
patritumab deruxtecan
3
Gemcitabine
3
Docetaxel
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
Histamine H2 Antagonists
2
Histamine Antagonists
2
Dexamethasone
2
Acetaminophen
2
130-nm albumin-bound paclitaxel
2
trastuzumab deruxtecan
1
osimertinib
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
enzalutamide
1
cemiplimab
1
Vascular Endothelial Growth Factor A
1
Serotonin 5-HT3 Receptor Antagonists
1
Ramucirumab
1
Oxaliplatin
1
Neurokinin-1 Receptor Antagonists
1
Neoadjuvant Therapy
1
Levoleucovorin
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dexamethasone
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled
NCT06788912
2026-05-26
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled